X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Wockhardt with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT LTD. vs PANACEA BIOTECH - Comparison Results

WOCKHARDT LTD.    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT LTD. PANACEA BIOTECH WOCKHARDT LTD./
PANACEA BIOTECH
 
P/E (TTM) x -18.2 -6.7 - View Chart
P/BV x 1.9 2.0 96.1% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 WOCKHARDT LTD.   PANACEA BIOTECH
EQUITY SHARE DATA
    WOCKHARDT LTD.
Mar-18
PANACEA BIOTECH
Mar-14
WOCKHARDT LTD./
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,012149 680.6%   
Low Rs53282 645.8%   
Sales per share (Unadj.) Rs355.984.1 422.9%  
Earnings per share (Unadj.) Rs-60.3-18.3 329.3%  
Cash flow per share (Unadj.) Rs-46.8-6.7 698.1%  
Dividends per share (Unadj.) Rs0.010-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs257.883.7 308.0%  
Shares outstanding (eoy) m110.6361.25 180.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.21.4 158.0%   
Avg P/E ratio x-12.8-6.3 202.9%  
P/CF ratio (eoy) x-16.5-17.2 95.7%  
Price / Book Value ratio x3.01.4 217.0%  
Dividend payout %00-   
Avg Mkt Cap Rs m85,3797,074 1,206.9%   
No. of employees `0006.32.8 227.4%   
Total wages/salary Rs m9,3711,449 646.6%   
Avg. sales/employee Rs Th6,295.01,874.1 335.9%   
Avg. wages/employee Rs Th1,498.3527.0 284.3%   
Avg. net profit/employee Rs Th-1,066.3-407.7 261.5%   
INCOME DATA
Net Sales Rs m39,3695,154 763.9%  
Other income Rs m1,202100 1,204.7%   
Total revenues Rs m40,5715,254 772.3%   
Gross profit Rs m18-766 -2.4%  
Depreciation Rs m1,495711 210.3%   
Interest Rs m2,5551,503 170.0%   
Profit before tax Rs m-2,830-2,881 98.2%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m-3,5821,771 -202.3%   
Tax Rs m25717 1,529.8%   
Profit after tax Rs m-6,669-1,121 594.7%  
Gross profit margin %0-14.9 -0.3%  
Effective tax rate %-9.1-0.6 1,557.3%   
Net profit margin %-16.9-21.8 77.9%  
BALANCE SHEET DATA
Current assets Rs m33,7963,810 887.0%   
Current liabilities Rs m26,9178,365 321.8%   
Net working cap to sales %17.5-88.4 -19.8%  
Current ratio x1.30.5 275.7%  
Inventory Days Days79156 51.0%  
Debtors Days Days8967 132.7%  
Net fixed assets Rs m39,66414,480 273.9%   
Share capital Rs m55361 902.4%   
"Free" reserves Rs m27,968903 3,096.9%   
Net worth Rs m28,5225,127 556.3%   
Long term debt Rs m21,7315,832 372.6%   
Total assets Rs m81,62019,433 420.0%  
Interest coverage x-0.1-0.9 11.7%   
Debt to equity ratio x0.81.1 67.0%  
Sales to assets ratio x0.50.3 181.9%   
Return on assets %-5.02.0 -256.6%  
Return on equity %-23.4-21.9 106.9%  
Return on capital %-7.73.6 -211.0%  
Exports to sales %024.5 0.0%   
Imports to sales %010.2 0.0%   
Exports (fob) Rs mNA1,264 0.0%   
Imports (cif) Rs mNA525 0.0%   
Fx inflow Rs m9,8071,539 637.2%   
Fx outflow Rs m1,789942 189.9%   
Net fx Rs m8,019597 1,342.7%   
CASH FLOW
From Operations Rs m684599 114.2%  
From Investments Rs m6,302-438 -1,439.2%  
From Financial Activity Rs m-7,695-303 2,542.9%  
Net Cashflow Rs m-664-141 469.9%  

Share Holding

Indian Promoters % 74.5 74.5 100.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.3 0.6 383.3%  
FIIs % 7.7 1.3 592.3%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 23.6 65.3%  
Shareholders   67,757 10,259 660.5%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT LTD. With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  PFIZER  ALKEM LABORATORIES  

Compare WOCKHARDT LTD. With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Prepare to Ride Out Volatile Markets with Rahul Shah(Podcast)

Watching the stock market basically volatile on a regular basis isn't easy. Catch Rahul Shah talk about his mantra to ride out the volatility in times like these.

Related Views on News

PANACEA BIOTECH Announces Quarterly Results (2QFY19); Net Profit Down 1631.6% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, PANACEA BIOTECH has posted a net profit of Rs 975 m (down 1631.6% YoY). Sales on the other hand came in at Rs 1 bn (down 22.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (2QFY19); Net Profit Down 158.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, WOCKHARDT LTD. has posted a net profit of Rs 228 m (down 158.2% YoY). Sales on the other hand came in at Rs 11 bn (up 10.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT LTD. SHARE PRICE


Dec 7, 2018 (Close)

TRACK WOCKHARDT LTD.

  • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT LTD.

WOCKHARDT LTD. - J.B.CHEMICALS COMPARISON

COMPARE WOCKHARDT LTD. WITH

MARKET STATS